Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Verquvo
| Field | Information |
|---|---|
| Medication Name | Verquvo |
| Generic Name | Vericiguat |
| Boxed/Label Warning | Do not use in pregnancy. |
| Purpose | Treatment of heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event. |
| Mechanism of Action | Stimulates soluble guanylate cyclase (sGC), leading to increased cyclic GMP (cGMP) and vasodilation. |
| Dosage Forms | Oral tablets |
| Available Strengths | 2.5 mg, 5 mg, 10 mg |
| Dosage Frequency | Once daily |
| Common Side Effects | Hypotension (low blood pressure), dizziness |
| Serious Side Effects | Symptomatic hypotension, fetal harm (contraindicated in pregnancy), anemia |
| Drug Interactions | PDE-5 inhibitors (e.g., sildenafil, tadalafil), nitrates, riociguat. |
| Important Notes | Monitor blood pressure regularly. Avoid use with PDE-5 inhibitors. Inform your doctor if you are pregnant or planning to become pregnant. |
| Storage | Store at room temperature away from moisture and light. |
| Missed Dose | Take as soon as you remember unless it is close to your next scheduled dose. Do not double the dose. |
| Alternatives | Entresto (sacubitril/valsartan), Jardiance (empagliflozin), Farxiga (dapagliflozin), Spironolactone |
Verquvo Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Entresto (sacubitril/valsartan) | Angiotensin receptor-neprilysin inhibitor (ARNI) | Reduces strain on the failing heart. |
| Jardiance (empagliflozin) | Sodium-glucose co-transporter 2 (SGLT2) inhibitor | Originally for diabetes, but also treats heart failure with reduced ejection fraction. |
| Farxiga (dapagliflozin) | Sodium-glucose co-transporter 2 (SGLT2) inhibitor | Similar to Jardiance, also treats heart failure with reduced ejection fraction. |
| Spironolactone | Aldosterone antagonist (potassium-sparing diuretic) | Reduces fluid retention and blood pressure. |
Verquvo Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Hypotension (low blood pressure) | Symptomatic hypotension (dizziness, lightheadedness) |
| Dizziness | Fetal harm (if taken during pregnancy) |
| Anemia | Anemia |
Verquvo Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Heart Failure with Reduced Ejection Fraction (HFrEF) | 2.5 mg once daily | Target maintenance dose is 10 mg once daily, as tolerated. Double the dose approximately every 2 weeks to reach target maintenance dose. | Take with or without food. Monitor blood pressure. |
Verquvo Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $10 – $100 |
| Without Insurance (U.S.) | $650 – $830 |
| From Canada | $110 |
